Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
People who started treatment on the same day as their HIV diagnosis achieved an undetectable viral load sooner.
Low-barrier care and access to multiple services in one place can improve outcomes for people experiencing homelessness or unstable housing.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
Better integration and transition planning was associated with higher rates of viral suppression among youth with HIV.
UPDATE: Data from 2019 and 2020 have been added to America’s HIV Epidemic Analysis Dashboard (AHEAD), an interactive digital map.
Study finds that Cabenuva administered every other month maintains viral suppression for two years.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
An HIV clinic saw a 31% lower likelihood of viral suppression after transitioning to telehealth due to COVID-19.
A new CDC model shows the potential power of Undetectable = Untransmittable to curb HIV rates by 2027.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
Kenya has been using similar technology for three years. DC’s efforts are among the first in the United States.
Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.
The HIV regimen failed only a few study participants.
Larger studies suggest people living with HIV might have a modestly higher risk of severe COVID-19, but much remains to be learned.
SARS-CoV-2 may have subtle effects on immunological and virological outcomes among people with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.